HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 7907 as of 27 May 15:30.
  • The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2020 .The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2020.
  • The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2020 .The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 1.57 crore as of March 2020.
  • The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 448.27 crore. This represent the decline of -100% The revenue of Novelix Pharmaceuticals Ltd for the Mar '25 is ₹ 20.86 crore as compare to the Dec '24 revenue of ₹ 5.3 crore. This represent the growth of 293.58%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 51.42 crore. This represent the decline of -100% The ebitda of Novelix Pharmaceuticals Ltd for the Mar '25 is ₹ 0.23 crore as compare to the Dec '24 ebitda of ₹ 0.13 crore. This represent the growth of 76.92%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 53.86 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ -0.17 crore to ₹ 0.18 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Novelix Pharmaceuticals Ltd

  • Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
  • Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
  • They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
  • Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

Astrazeneca Pharma India Ltd News Hub

News

Astrazeneca Pharma India announces board meeting date

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 3...

Read more

22 May 2025 16:02

News

AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)

The newly approved indication allows Osimertinib to be used in combination with pemetrexed...

Read more

05 Apr 2025 14:43

News

Astrazeneca Pharma gains after receiving approval from CDSO to import Durvalumab solution.

Through this approval, Durvalumab in combination with Tremelimumab is indicated for the tr...

Read more

03 Mar 2025 14:43

News

Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr

Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.7...

Read more

12 Feb 2025 11:47

News

Astrazeneca Pharma India to hold board meeting

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...

Read more

21 Jan 2025 10:45

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Happiest Minds Technologies Ltd, Campus Activewear Ltd, Cera Sanitaryware Ltd, ITI Ltd are...

Read more

30 Dec 2024 14:30

Novelix Pharmaceuticals Ltd News Hub

News

Novelix Pharmaceuticals to convene board meeting

Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27...

Read more

21 May 2025 16:50

News

Novelix Pharmaceuticals to convene EGM

Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Comp...

Read more

15 Apr 2025 10:33

News

Trimurthi to table results

Trimurthi will hold a meeting of the Board of Directors of the Company on 12 February 2025...

Read more

08 Feb 2025 10:47

News

Trimurthi to announce Quarterly Result

Trimurthi will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

09 Nov 2024 17:04

News

Trimurthi revises board meeting date

Trimurthi has revised the meeting of the Board of Directors which was scheduled to be held...

Read more

14 Oct 2024 10:29

News

Trimurthi to hold board meeting

Trimurthi will hold a meeting of the Board of Directors of the Company on 14 October 2024....

Read more

08 Oct 2024 10:44

SWOT Analysis Of Novelix Pharmaceuticals Ltd

Strength

0

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Novelix Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 19,768 Cr while Market cap of Novelix Pharmaceuticals Ltd is 69 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd?

As of May 27, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹7907.5. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹27.94.

How do dividend payouts of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions